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Abstract
Objectives To compare the acute success and short-term
follow-up of ablation of atrial flutter using 8 mm tip
radiofrequency (RF) and cryocatheters.
Methods Sixty-two patients with atrial flutter were ran-
domized to RF or cryocatheter (cryo) ablation. Right atrial
angiography was performed to assess the isthmus. End
point was bidirectional isthmus block on multiple criteria.
A pain score was used and the analgesics were recorded.
Patients were followed for at least 3 months.
Results The acute success rate for RF was 83% vs 69% for
cryo (NS). Procedure times were similar (mean 144±48min
for RF, vs 158±49 min for cryo). More applications were
given with RF than with cryo (26±17 vs. 18±10, p<0.05).
Fluoroscopy time was longer with RF (29±15 vs. 19±
12 min, p<0.02). Peak CK, CK-MB and CK-MB mass were
higher, also after 24 h in the cryo group. Troponin T did not
differ. Repeated transient block during application (usually
with cryoablation) seemed to predict failure. Cryothermy
required significantly less analgesia (p<0.01), and no use of
long sheaths (p<0.005).
The isthmus tended to be longer in the failed procedures
(p=0.117). This was similar for both groups, as was the
distribution of anatomic variations. Recurrences and com-
plaints in the successful patients were similar for both
groups, with a very low recurrence of atrial flutter after
initial success.
Conclusions In this randomized study there was no
statistical difference but a trend to less favorable outcome
with 8 mm tip cryocatheters compared to RF catheters for
atrial flutter ablation. Cryoablation was associated with less
discomfort, fewer applications, shorter fluoroscopy times
and similar procedure times. The recurrence rate was very
low. Cryotherapy can be considered for atrial flutter
ablation under certain circumstances especially when it
has been used previously in the same patient, such as in an
AF ablation.
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1 Introduction
Atrial flutter is a common arrhythmia [1], difficult to
suppress with medication [2], and is associated with
significant symptoms. Since it was first proposed [3–5],
ablation for atrial flutter has increasingly been used for its
therapy, especially since induction of bidirectional cavo-
tricuspid isthmus block was shown to be associated with
better immediate outcomes and lower recurrence rates [6–
11]. Failure to successfully ablate atrial flutter in the long-
term may be due to particular anatomic problems [12–14],
poor catheter stability in this region, and incorrect interpre-
tation of isthmus block. Important developments in the field
of atrial flutter ablation have been a better understanding of
the anatomy of the isthmus, refinements of the definition of
bidirectional isthmus block, and the arrival of new catheter
technology.
Numerous studies have compared different energy types,
different catheter tip sizes and different energy settings [15–
19], as well as the use of advanced cardiac mapping
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systems [20]. The preferred tools now are 8 mm, or
irrigated tip catheters [21]. From a recent meta-analysis it
would appear that these two technologies are equally
effective with acute success quoted at 84% and 85% for
the primary catheter chosen before changeover, whereafter
final success rates of up to 99% can be achieved [22]. Not
all studies have this high success rate and the preponder-
ance of studies on ablation of atrial flutter suggest that these
high success rates are not repeated in all centers [23]. Also of
importance is a clinical recurrence rate, in the face of acute
success, of at least 5 to 12% when using radiofrequency [19,
24, 25]. Disadvantages of radiofrequency (RF) energy
include pain, overheating with “popping”, char formation
and risk to coronary arteries.
Cryoablation is a relatively recent addition to the
transvenous ablation armamentarium and has been shown
to be comparable to RF for some arrhythmias. It may have
some advantages over RF, especially as regards discomfort
during ablations [17, 26]. The development of 6 and 8 mm
tip cryocatheters has increased the interest in this technology
for atrial flutter ablation. As far as we are aware there have
been no randomized comparative studies published compar-
ing 8 mm tip cryocatheters with 8 mm tip RF catheters.
2 Methods
2.1 Patient population
Consecutive patients with ongoing symptoms and docu-
mented atrial flutter with or without fibrillation were
included. At least one recent episode of atrial flutter (within
the last 6 months) was documented on a 12 lead ECG and
was suggestive for isthmus dependency. Patients with drug-
induced flutter (and prior AF) could be included, and had
their drug therapy continued after ablation. Patients were
excluded if they had undergone a previous flutter ablation,
if thrombus was present in the atria, or after previous
cardiac surgery for valvular or congenital heart disease.
Baseline investigations included a standard echocardio-
gram, a simple questionnaire asking about clinical well-
being and a subjective assessment of the arrhythmia burden
both in terms of duration and frequency. The study was
approved by the ethics committee of our institution. All
patients signed written informed consent.
2.2 Assessment before ablation
Antiarrhythmic drugs, except for AV nodal slowing agents,
and amiodarone, were discontinued at least five half-lives
prior to ablation. Patients were studied in the fasting, post-
absorptive state. A coronary sinus (CS) catheter was
inserted through the left subclavian vein, and a multipolar
circular right atrial catheter with alternating 2–10–2 mm
interelectrode distance was positioned from the right groin,
with the tip positioned immediately lateral to the planned
position of the isthmus line and anterior to the crista terminalis.
Heparin 100 U/kg was given and a further 5 U/kg given if the
procedure lasted longer than 180 min.
If the patient was in sinus rhythm, isthmus conduction
was confirmed by pacing. If flutter was present, entrain-
ment was performed to confirm isthmus dependence, and
the patient left in flutter. If AF was present, the patient was
cardioverted after a transoesophageal echocardiogram, and
then isthmus conduction confirmed. Absence of isthmus
conduction or non-isthmus dependence was not seen in the
selected patients. No induction of arrhythmia was attempted
if patients had sinus rhythm.
Radiological assessment of the right atrial isthmus was
made in a right anterior oblique (RAO) 30°, and a left anterior
oblique (LAO) 45° view (each with 40 cc at 18 cc/s).
Angiograms were acquired digitally to allow for post-hoc
analysis. The treating physician was able to view the
angiographic findings to optimize the planned ablation line.
The isthmus length was assessed from the inferior hinge point
of the tricuspid valve to the IVC at the end of atrial diastole
(the frame before opening of the tricuspid valve) [14].
Morphology was assessed visually as to the presence of a
Eustachian valve or a recess, as well as to the general shape
i.e. flat or concave.
2.3 Ablation procedure
The catheters were a 9Fr 8 mm tip catheter (FreezorMax,
Cryocath Technologies Inc, Kirkland, Canada) with a
cryoconsole for the cryoablation group, and a 7Fr 8 mm
tip single sensor catheter (EPT Blazer II, Boston Scientific,
Natick, MA, USA) with an EPT-1000XP generator for the
radiofrequency group. A large curve was initially selected
in both groups, with change out of catheter curve during the
study only as necessary. Applications of −75°, for 4 min
were given with cryothermy, and applications of 60 Watt,
for 60 s, targeted at 60°C for RF. Lines were made with
discrete applications between the tricuspid valve and the
inferior vena cava at an approximately 6 o’clock position in
LAO 45°, unless otherwise dictated. If termination of atrial
flutter occurred, or if the patient was in sinus rhythm,
continuous pacing from the proximal coronary sinus was
employed to continually assess isthmus conduction. After
the first line, a new assessment of conduction was
performed. If conduction over the isthmus remained
present, gaps were sought. If there was still isthmus
conduction, a slightly more medial or lateral line was
made. In no patient was an attempt made to perform a
septal ablation line. Final assessment of acute block was
confirmed after 30 min waiting.
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The end point for successful ablation was induction of
complete bidirectional isthmus block, defined as the
presence of reversal of activation on the lateral and septal
wall when pacing the CS os and low lateral RA, the
presence of widely split potentials along the isthmus line,
by activation mapping across the isthmus, and by differen-
tial pacing. All 4 were required before calling the ablation
successful. In the case where bidirectional block was not
achieved, ablation was stopped when no large, sharp signals
could be identified over a broad area of the isthmus.
As pain perception was assessed, sedation was standard-
ized. Before venous puncture 5 mg of diazepam was given
intravenously, and repeated at the patient’s request. Fen-
tanyl 50 μg intravenously was given when the patient
requested pain control and the physician considered this
necessary. This was repeated as needed. Dosages of both
diazepam and fentanyl were recorded.
In the initial 40 patients creatine kinase (CK) and CK-
MB were taken before the procedure, 2 and 24 h after the
start of the procedure. For the final 22 patients the
laboratory had changed the measurement to CK mass. We
then modified the protocol to measure CK-MB mass,
Troponin T, and Myoglobin at 4 and 24 h after the start
of the procedure.
No crossover, other than in catheter curve, was allowed
in an attempt to remove any possible bias. Change over to
an irrigated tip ablation catheter was also not allowed. In
patients in whom no block could be induced, a repeat
procedure was scheduled not earlier than 6 weeks after the
initial ablation, at the physicians’ discretion. The choice of
energy source at that time was at the physicians’ discretion.
Patients were all questioned with regard to pain
perception using a visual analogue score, where patients
are shown a line from 0 to 10, where 0 is no pain, and 10 is
the highest pain level imaginable, and were asked to point
to the position on the line where their pain level during
ablation was.
2.4 Follow-up
All patients received an event-recorder for the first 6 weeks
after the procedure and were requested to send at least daily
strips as well as strips made during symptoms. Patients
visited the outpatient clinic 6 weeks after the procedure.
After this period all patients were asked to report symptoms
and if these were present were given a further event monitor
until documentation of symptoms was obtained. If at all
possible a 12 lead ECG was also obtained. A second
assessment with a questionnaire was performed after
3 months, again asking a question about general clinical
well being and also symptom burden in regard to duration
and frequency. Clinical files were followed up after
9 months.
2.5 Statistical analysis
For patients in whom another ablation was performed
(AVNRT in two, and pulmonary vein ablation in six others)
procedure and fluoroscopy times were limited to the flutter
approach, which was done first, including 30 min waiting
time. Biomarker assessment was not done in these patients.
Continuous variables are expressed as mean ± standard
deviation, with medians as necessary. Parametric and non-
parametric tests were used where appropriate. A p-value of
<0.05 was considered significant.
3 Results
3.1 Patient data
62 patients were included as planned, with clinical
characteristics as outlined in Table 1. There were no
significant differences in any of the parameters between
the group assigned to radiofrequency (RF group) versus
that assigned to cryotherapy (cryo group). The large
number of patients with prior AF is due to the fact that
we had initially taken a decision to perform isthmus
ablation first in all patients with AF who had shown typical
atrial flutter on any 12-lead ECG, prior to performing a left
atrial procedure, initially in a separate procedure and only
later in the same session.
3.2 Angiographic data
Right atrial angiography was not performed in 4 patients
because of mild renal dysfunction or allergy to contrast
material. The angiogram was of insufficient quality in eight
others.
The mean isthmus length was 35.2±14.6 mm and its
topography was assessed as being flat or only mildly
concave in 28, markedly concave in 19 and showed a pit or
aneurysm in 10. A clear Eustachian valve was seen on six
angiograms.
Table 1 Demographics
All Cryo RF p value
Number 62 32 30
Age (years±SD) 56±10 55±11 56±9 NS
Male/female 27/5 27/5 28/2 NS
Atrial fibrillation
history
47 (76%) 25 (78%) 22 (73%) NS
Cryo Cryoablation; NS not significant; RF radiofrequency; SD
standard deviation
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3.3 Ablation data
Assessment of acute results showed bidirectional isthmus
block, using the criteria mentioned, in 47 of 62 patients
(76%). This was in 25 of 30 patients (83%) of the RF group
and in 22 of 32 (69%) of the cryo group (NS). In 1 patient
in the RF group the procedure was terminated because of
recurrent AF with early recurrence and inability to assess
isthmus block. This patient was taken as a failure which
was confirmed at the time of a subsequent AF ablation.
Procedural data for all patients are given in Table 2.
In the successful patients the number of applications to
ensure block in the whole group was 17±11. It was 23±13
in the RF group and 12±6 in the cryo group (p<0.005).
Total ablation time was 1,283±777 s and 2,905±1,245 s
(p=0.0001). In those in whom bidirectional block could not
be achieved, the total number of applications was 33±14.
For RF and cryo the values were 39±21 applications with a
total time of 2,724±1,102 s vs 29±8 applications with a
time of 5,873±1,337 s (p<0.03 and <0.0011, respectively).
In 22 of 30 in the RF group and 25 of 32 in the cryo
group, a single line at approximately 6 o’clock was drawn.
In the RF group two lines were drawn in seven, and three in
one. In the cryo group two lines were made in four, and
three lines in three. The need to draw more than one line
was associated with failure of the procedure in four of eight
in the RF group and five of seven in the cryo group (NS).
Short lived block, either recurring during the application
or immediately thereafter, occurred in one patient in the RF
group and in six in the cryo group, with a trend to statistical
significance (p=0.091), with it being a predictor of failure
if it occurred more than three times. In five patients in the
RF group and one patient in the cryo group, conduction
recurred later during a waiting period (with a median of
15 min) requiring further applications (NS). In only one
patient in the RF group was late recurrence associated with
failure to induce bidirectional block. In no patient in whom
bidirectional block was present at the end of the 30 min
waiting period did isoprenaline change this. The average
power applied in the RF group was 52±6 W.
In the RF group the signal was significantly diminished
at the end of each application whether isthmus block was
present or not, while there tended to be preservation of
signals on the cryoablation catheter after ablation across the
isthmus until block occurred. Only then were low voltage
signals seen.
Failures were not significantly associated with length of
the isthmus (39.2±23.5 vs 34±9.0 mm in success, although
there was a trend to this (p=0.12) There was no significant
difference in anatomy between the two groups.
3.4 Procedure data and complications
The overall procedure time was 160±49 min, with no
difference between 170±48 min in the RF group and 151±
49 min in the cryo group. Overall fluoroscopy times were
28±14 min, with a difference between 33±15 min in the
RF group and 23±11 min in the cryo group (p<0.02).
Change of catheter curve occurred in one patient in the
RF group from large to standard curve. An SL1 sheath
Table 2 Procedure data and recurrent arrhythmias
All Cryo RF p value
Number 62 32 30
Application number 22±13 18±10 25±16 0.05
Ablation time (s) 2,742±1,930 3,792±1,900 1,459±950 <0.001
Acute success 47 (76%) 22 (69%) 25 (83%) NS
Single line 47 (76%) 25 (78%) 22 (73%) NS
2 lines 9 (15%) 2 (6%) 7 (24%) 0.073
3 lines 4 (6%) 3 (9%) 1 (3%) NS
Reversal of block during application 7 (11%) 6 (19%) 1 (3%) 0,091
Reversal of block during 30 min 6 (10%) 1 (3%) 5 (7%) NS
Isthmus length (mm) 35±15 35±17 36±11 NS
Sheath usage 7 (11%) 0 (0%) 7 (23%) <0.005
Recurrent arrhythmias
Flutter (typical)
After success 1 (2%) 0 (0%) 1 (4%) NS
After failure 11 (73%) 7 (70%) 4 (50%) NS
Flutter (atypical) 1 (2%) 0 (0%) 1(3%) NS
Atrial tachycardia 5 (8%) 2 (6%) 3 (10%) NS
Atrial fibrillation 28 (45%) 13 (41%) 15 (50%) NS
The numbers are given with the standard deviation.
Cryo Cryoablation; NS not significant; RF radiofrequency
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(Daig, Minnetonka, MN, USA) was used in seven patients
in the RF group for stability, while no sheath usage
occurred in the cryo group (p=0.005). During the proce-
dure, six patients required cardioversion for induced AF,
four in the RF group and two in the cryo group (NS). There
were two small pericardial effusions seen on echocardiog-
raphy without further significance (one in each group).
For the initial 40 patients there was a significantly higher
peak CK and CK-MB after cryo (Table 3). This remained
so after 24 h. For the last 22 patients we observed the same
for CK-MB mass, but not for Troponin T (Table 3).
In assessing the level of comfort during the procedure
and the pain experienced by patients, similar numbers from
both groups assessed sedation as adequate (67% for RF and
63% for cryo). The pain scores given at the end of the
procedure were not significantly different (42.9±24.0 for
RF and 43.7±15.8 for cryo). Diazepam was given as
standard at the beginning of the procedure and as necessary
thereafter for discomfort related to having to lie still for
protracted periods. The usage of diazepam was statistically
similar in both groups (7.4±3.4 mg in the RF group and
8.0±3.1 mg in the cryo group). However, a significantly
higher usage of fentanyl in the RF group was observed
(70.0±44.9 μg vs 10.0±22.1 μg; p<0.01).
3.5 Follow-up results
Patients were followed up for between 90 and 411 days
(138±81 days, median 90 days), which was similar in both
groups (p=ns).
A total of 6 patients were taking no antiarrhythmic
medication prior to ablation and this increased to 13 post
isthmus ablation.
Recurrent arrhythmias were frequent in both groups of
patients. ECG documented recurrent flutter occurred only
in one patient from the RF group. A further procedure
confirmed recovery of isthmus conduction. This recurrence
was seen at 14 months post ablation, whereas he had
previously had monthly episodes of flutter. One other
patient had symptoms with an apparently non-isthmus
dependent flutter documented on ECG on day 1 post
ablation and not since, and elected not to have a further
procedure. We cannot exclude asymptomatic arrhythmias
but at least during the first 6 weeks, patients sent in daily
event monitor transmissions, which one would hope would
have captured at least some asymptomatic recurrences,
particularly of atrial flutter.
In 11 of 15 patients in whom the initial procedure failed,
a redo procedure was performed after the elected period of
6 weeks because of documented recurrent flutter. The redo
procedure required a small number of point touch ups in
five patients (three in the RF group and two in the cryo
group), while more extensive diffuse isthmus applications
were required in six (one in the RF group and five in the
cryo group). In those undergoing repeat ablation, success
was achieved in all and during follow up no recurrent atrial
flutter was noted.
Previously undocumented atrial tachycardias were also
seen in both groups (three in the RF group, and two in the
cryo group). ECG documented AF recurrence occurred in
28 patients, at a similar rate in both groups (15 in the RF
group and 13 in the cryo group). The likelihood of
asymptomatic recurrences is probably higher for atrial
fibrillation but was not the primary focus of this study.
4 Discussion
4.1 Acute success
This study showed an acute success rate of 83% for an
8 mm tip RF catheter vs. 69% for an 8 mm tip cryocatheter.
This non significant difference is clearly concerning.
However, the cryoablation group required significantly less
applications to achieve success, with a similar procedural
duration, significantly lower fluoroscopy time, and with a
much lower requirement for analgesia with fentanyl.
Arrhythmia recurrences in the initially successful patients
were similar with a very low flutter recurrence rate.
The acute success rate with 8 mm tip RF compares
favorably with that found in the meta-analysis of Da Costa
et al. [22]. However, the acute results for cryotherapy are
lower than in previously published studies. The shorter
fluoroscopy time using cryotherapy is related to cryoadher-
ence during applications [26]. With the catheter firmly
attached, no fluoroscopy to check position is required. This
Table 3 Biomarkers after catheter ablation
All Cryo RF p value
Procedure values
CK (U/l) 141±96 184±102 96±60 0.02
CK-MB (U/l) 27±16 36±17 18±8 0.011
CK-MB mass (μg/l) 18±21 33±24 4.4±1.2 0.004
Troponin T (μg/l) 0.49±
0.32
0.54±
0.38
0.39±
0.27
NS
Values after 24 hrs
CK (U/l) 264±245 289±173 136±74 0.022
CK-MB (U/l) 37±28 51±30 18±6 0.011
CK-MB mass (μg/l) 8.4±7.3 12±10 5.16±3.3 0.07
Troponin T (μg/l) 0.44±
0.30
0.54±
0.36
0.38±
0.29
NS
The numbers are given with the standard deviation.
CK Creatine kinase; Cryo cryoablation; NS not significant; RF
radiofrequency
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is also reflected in the fact that no long sheaths were
necessary. A lower requirement for analgesia has previously
been described and this study confirms this finding [17, 26].
4.2 Difficulties during ablation
Recurrence during or shortly after ablation occurring more
commonly in the cryo group probably relates to a reversible
cooling effect at the periphery of the ice ball which recovers
during or shortly after termination of ablation, while the
central lesion acutely formed is more permanent. The more
common recurrence during the waiting period after RF
ablation probably relates to a longer reversal time of the
acute RF effects (either edema or temperature effect).
4.3 Cryoablation for flutter
Cryoablation may have some advantages over RF in
addition to those mentioned above such as less thrombo-
genicity [27], and maintenance of tissue architecture with
homogenous well delineated lesions [28]. A 10Fr, 6.5 mm
tip catheter showed acute success of 94–100% and 6 month
recurrence rates of 0–25% [17, 29, 30]. A system with 7Fr,
6 mm tip catheters showed success in 87% to 88% using a
septal line, without symptomatic recurrences, but with
resumption of isthmus conduction at repeat study at
6 months in 30–35% [31, 32]. Using a 9Fr, 8 mm tip
increased success rates to100% with symptomatic recur-
rence of 0% to 10% and recurrent conduction at 1 to
3 months in 19% to 32% [32–34]. There is some discussion
as to whether 3, 4 or 8 min of ablation are needed for
adequate lesion formation [33, 35].
Higher peak CK levels, confirmed by the high CK-mass
in the last patients, suggest that the damage caused by
cryotherapy may be more extensive despite the lower
number of applications. Several explanations are possible.
The first is that the CK levels may be underestimated after
RF, which denatures proteins in another way than cryother-
apy. Troponin T levels are more accurate in estimation of
myocardial damage, but they also tended to be higher, be it
not significantly. This may suggest that lesions are equal
with both approaches.
4.4 Future developments
Newer data suggest that ablation per point guided by the
maximal voltage may be a useful technique, but this has not
been confirmed for cryotherapy [36].
4.5 Study limitations
This study was a single centre, largely single operator study
involving a relatively limited number of patients with a
high population of AF patients, making follow-up rather
complicated. In present practice and later in this series,
patients with the combination are often treated in one
session, which still leaves physicians the choice whether
cryo should be used for flutter, following its use for the
pulmonary veins [37]. We only studied the acute and short-
term success, while flutter recurrence may happen at more
than 4 months of follow-up. While we attempted to exclude
asymptomatic recurrences especially in the first 6 weeks,
we cannot exclude the possibility of these, especially of AF
and also late after the ablation. Isthmus conduction
recovery is also possible in asymptomatic cases. In the RF
group we limited the power to 60 W to ensure safety and
this may be too conservative. Further, in our practice
routine use of long sheaths was discouraged. At the time of
this study use of an 8 mm tip with RF was considered as
effective as irrigated tip ablation, so we elected to use this
approach for the RF group. More recent studies have shown
higher success rates than we obtained and have also
suggested alternatives in the approach. These include the
use of irrigated tip catheters and long sheaths as well as
other technical issues and newer techniques such as maximal
voltage guided ablation. A higher success rate for RF would
clearly have been even more prejudicial to cryotherapy in
this study. We were also extremely critical in our assessment
of isthmus conduction, using multiple criteria. Angiograms
were also performed in fixed views and not based on other
catheter positions as has been suggested by others [14].
5 Conclusion
Acute success with cryotherapy for atrial flutter ablation,
while non-statistically less effective in this study, requires
fewer applications and is associated with a significantly
lower requirement for pain relief. While our acute results
for both cryotherapy and RF may not be as high as those in
some comparable studies the recurrence rate was only 2.5%
in the RF group, with no clinical recurrence in the cryo
group. While cryotherapy cannot perhaps be advocated as
first line therapy, it may be useful in certain circumstances.
Certainly, if cryoablation is performed for AF, and if the
isthmus needs to be ablated, cryotherapy might be used as
well [37].
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